<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We investigated the efficacy of an antithymocyte globulin/<z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> preparative regimen prior to allogeneic stem cell transplantation from HLA-identical siblings in patients with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Since 1990, 21 patients, 6 males and 15 females, with a median age of 25 years (range: 7-43) have been enrolled in the protocol consisting of 200 mg/kg <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> and 90-120 mg/kg antithymocyte globulin (ATG, rabbit, Fresenius, Bad Homburg, Germany) </plain></SENT>
<SENT sid="2" pm="."><plain>For further <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) prophylaxis <z:hpo ids='HP_0000001'>all</z:hpo> patients received <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> and a short course of <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (MTX) </plain></SENT>
<SENT sid="3" pm="."><plain>Only one patient had a primary graft failure (5%) </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> other patients engrafted with a leukocyte count &gt;1.0 x 10(9)/l and a platelet count &gt;20 x 10(9)/l after a median of 19 (range: 11-28) and 26 days (range: 13-67), respectively </plain></SENT>
<SENT sid="5" pm="."><plain>No late graft failure or relapse was observed </plain></SENT>
<SENT sid="6" pm="."><plain>Two patients experienced mild <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD grade I (10%), and one patient developed grade II GVHD (5%) </plain></SENT>
<SENT sid="7" pm="."><plain>No severe grade III/IV GVHD was observed; 17% of the patients developed limited <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD </plain></SENT>
<SENT sid="8" pm="."><plain>The treatment-related mortality was 14% and mainly due to <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal infection</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>After a median follow-up of 70 months (range: 2-139), the estimated overall and event-free survival at 10 years for <z:hpo ids='HP_0000001'>all</z:hpo> patients is 86% (95% confidence interval: 70-100%) </plain></SENT>
<SENT sid="10" pm="."><plain>We conclude that ATG plus <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> is an effective conditioning regimen in patients with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> undergoing stem cell transplantation with a low treatment-related mortality, resulting in an excellent outcome </plain></SENT>
</text></document>